Navigation Links
Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
Date:10/9/2008

elopment of treatments for chronic cardiovascular conditions.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is carrying out clinical research to show the therapeutic benefits of its products in various medical indications. The Company patents and protects its innovations and is continuously expanding its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industry. Neptune has entered into agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Ambassador to Speak at Economic Cl...anada (Vocus) November 25, 2009 -- Ambassador to S...vid Appia, French Ambassador for International Inv...nce Agency ,To view a biography of David Appia go ...or Appia is available to meet with press to discus...
(Date:11/25/2009)...NDIEGO,Nov.25/PRNewswire-FirstCall/--ArdeaBioscien...art,Pharm.D.,presidentandchiefexecutiveofficer,wil...rence. , ,Presentationdetailsareasfollows:,Piper...,December1,2009,Time:2:00p.m.EasternTime,Location:...ttp://www.corporate-ir.net/ireye/,target=,_blank,...
(Date:11/24/2009)...NTACRUZ,Calif.,Nov.24/PRNewswire/--Twomoreprestigi...,sleadingonlinejobboardandcareerssiteforlifescienc...rsityarenowmembersofthejobboard,joining28othermajo...d, www.biocareercenter.com ,isonlyforpost-graduate...ncecareersitesontheInternet,BioCareerCenteristheon...
(Date:11/24/2009)...YKJAVIK,Iceland,November24/PRNewswire-FirstCall/--...heapprovalofallofits,"firstday"motionsbytheU.S.Ban...cyCourt").deCODElastweekfiledavoluntarypetitionfor...dewiththe,BankruptcyCourt. , Theordersissuedb...rateitsbusinessduringtheChapter11proceedings.Inpar...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...to serve Pacific Northwest, SEATTLE, Dec. 21 Ste... the western Washington state congressional delega...ng designated to help development,of a state-of-th...ncer Care,Alliance (SCCA). The money is included i...resident Bush on Thursday, Dec. 20., "The leaders...
...rmaceuticals, Inc. (Nasdaq: LXRX ) announced toda...g (IND) application to the U.S. Food and Drug,Admi...e for managing,gastrointestinal symptoms associate...nical trial of LX1032 is planned as a double-blind...dose study in healthy volunteers. This,study is de...
..., Conn., Dec. 20 /PRNewswire-,FirstCall/ -- Cell G...affiliate of GBP Capital, the majority shareholder...ounced that the two companies have entered,into an...ntiviral gene,delivery technology, commonly referr...ment, Cell Genesys has received a payment of $12 m...
Other Biology Technology:Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 2Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 3Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 2Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 3Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 2Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 3Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 4Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million 5
(Date:11/25/2009)....Scientists at the California Institute of Technol...ve emotion-like behavior in the fruit fly, Drosop...be relevant to the relationship between the neurot...ivity disorder (ADHD), are described in the Decemb...ila brain contains only about 20,000 neurons and ...
(Date:11/25/2009)...VEMBER 25, 2009 Soil is the linchpin of the envir...re meet. Despite that, many students see soil as "...re. Soil science educators are challenged with the... the critical importance of soil in the environmen...d earth science teachers at University of Nebraska...
(Date:11/24/2009)...rch Institute (LRI) today named 12 new grant recip... recognize innovative work across a broad spectrum...eativity, novelty, and potential to drive scientif...e the complex disease of systemic lupus. , The 2...searchers across the nation and include interdisci...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3NEW Momentum 28TM 29 Physician and Staff Scheduling Software for Imaging Centers OB GYN and Other Specialty Practices Improves Productivity and Equi 13024 1NEW Momentum 28TM 29 Physician and Staff Scheduling Software for Imaging Centers OB GYN and Other Specialty Practices Improves Productivity and Equi 13024 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 1Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 3Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 13022 4Was SIDS the cause of infant deaths even 150 years ago 3F 51625 1
... / - Cambridge Healthtech Institute’s Fifth ...7-29, 2009 at the Loews Philadelphia Hotel, Philad...dline for this event is April 10, 2009. , The sign...omarker Series, The Biomarker World Congress 2009 ... all areas of biomarker research spanning the phar...
...t ethnic groups store fat in their bodies may acco...lop insulin resistance and non-alcoholic fatty liv... Center have found. , According to research repo... Hepatology, African-Americans with insulin resis...this form of metabolic liver disease. , Despite s...
... Institute has obtained the first glimpse of a pro... drugs, out of cells. The protein, called P-glycop...ns cancer cells are resistant to chemotherapy drug... design more effective drugs. , The new research ...journal Science . , "This structure is an impor...
Other Biology News:CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 2CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 3CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 4CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 5Difference in fat storage may explain lower rate of liver disease in African-Americans 2Difference in fat storage may explain lower rate of liver disease in African-Americans 3Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 2Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 3
Mouse Anti-Human FBXO11 Monoclonal Antibody, Unconjugated, Clone 4C12 from Abnova Corporation
Mouse Anti-Human LASS3 Polyclonal Antibody, Unconjugated from Abnova Corporation
Rabbit Anti-Nonmuscle Myosin II Heavy Chain B (MHC-B) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
Rabbit Anti-Mi-2 Polyclonal Antibody, Unconjugated from Upstate
Biology Products: